Travere Therapeutics Pauses Enrollment In Phase 3 Study Of Pegtibatinase For Manufacturing Scale-Up
27/9 05:46
(RTTNews) - Travere Therapeutics Inc. (TVTX) announced a voluntary pause in enrollment for the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU). This decision follows the Company's determination that the desired drug substance pro...